...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Synthesis of new 4-(2-(alkylamino) ethylthio)pyrrolo(1,2-a)quinoxaline and 5-(2-(alkylamino) ethylthio)pyrrolo(1,2-a)thieno(3,2-e)pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors.
【24h】

Synthesis of new 4-(2-(alkylamino) ethylthio)pyrrolo(1,2-a)quinoxaline and 5-(2-(alkylamino) ethylthio)pyrrolo(1,2-a)thieno(3,2-e)pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors.

机译:合成新的4-(2-(烷基氨基)乙硫基)吡咯并(1,2-a)喹喔啉和5-(2-(烷基氨基)乙硫基)吡咯并(1,2-a)噻吩并(3,2-e)吡嗪衍生物,作为潜在的细菌多药耐药泵抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis of new 4-[2-(alkylamino)ethylthio]pyrrolo[1,2-a]quinoxaline derivatives la-1 is described in five or six steps starting from various substituted nitroanilines 2a-e. The bioisostere 5-[2-(alkylamino)ethylthio]pyrrolo[1,2- a]thieno[3,2-e]pyrazine 1m was also prepared. The new derivatives were evaluated as efflux pump inhibitors (EPIs) in a model targeting the NorA system of Staphylococcus aureus. The antibiotic susceptibility of two strains overproducing NorA, SA-1199B and SA-1, was determined alone and in combination with the neo-synthesised compounds by the agar diffusion method and MIC determination, in comparison with reserpine and omeprazole taken as reference EPIs. A preliminary structure-activity relationship study firstly allowed to clarify the influence of the substituents at positions 7 and/or 8 of the pyrrolo[1,2-a]quinoxaline nucleus. Methoxy substituted compounds, 1b and 1g, were more potent EPIs than the unsubstituted compounds (1a and 1f), followed by chlorinated derivatives (1c-d and 1h). Moreover, the replacement of the N,N-diethylamino group (compounds 1a-e) by a bioisostere such as pyrrolidine (compounds 1f-h) enhanced the EPI activity, in contrast with the replacement by a piperidine moiety (compounds 1i-k). Finally, the pyrrolo[1,2-a]thieno[3,2-e]pyrazine compound 1m exhibited a higher EPI activity than its pyrrolo[1,2-a]quinoxaline analogue la, opening the way to further pharmacomodulation.
机译:从各种取代的硝基苯胺2a-e开始,以五步或六步描述了新的4- [2-(烷基氨基)乙硫基]吡咯并[1,2-a]喹喔啉衍生物la-1的合成。还制备了生物立体异构的5- [2-(烷基氨基)乙硫基]吡咯并[1,2-a]噻吩并[3,2-e]吡嗪1m。在针对金黄色葡萄球菌的NorA系统的模型中,将新衍生物评估为外排泵抑制剂(EPI)。与以利血平和奥美拉唑为参考EPI相比,通过琼脂扩散法和MIC测定单独测定了两种过量生产NorA的菌株SA-1199B和SA-1的抗生素敏感性,并与新合成的化合物结合使用。初步的结构活性关系研究首先可以阐明吡咯并[1,2-a]喹喔啉核的7和/或8位取代基的影响。甲氧基取代的化合物1b和1g比未取代的化合物(1a和1f)更有效的EPI,其次是氯化衍生物(1c-d和1h)。此外,与N,N-二乙基氨基基团(化合物1a-e)被吡咯烷等生物化合物(化合物1f-h)取代增强的EPI活性,与哌啶基取代物(化合物1i-k)相反。最后,吡咯并[1,2-a]噻吩并[3,2-e]吡嗪化合物1m显示出比其吡咯并[1,2-a]喹喔啉类似物la更高的EPI活性,从而为进一步的药物调节开辟了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号